Breaking News

GHO Capital Invests in Cell Therapy CDMO RoslinCT

Aims to support operational growth, customer acquisition and product diversification.

Author Image

By: Charlie Sternberg

Associate Editor

Global Healthcare Opportunities, or GHO Capital Partners LLP, a European specialist investor, has invested in RoslinCT, a Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies.   Established in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was formed through an initial spin-out from the Roslin Institute, which has a famous track record in genetic and cellular biology.   Since 2014, the company has had a manufacturing base...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters